Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cel-Sci Corporation stock logo
CVM
Cel-Sci
$1.43
+10.0%
$3.29
$0.89
$13.48
$11.04M0.7700,046 shs1.11 million shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$9.40
-5.5%
$8.87
$4.82
$11.85
$921.11M1.23777,088 shs768,589 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cel-Sci Corporation stock logo
CVM
Cel-Sci
+8.33%-18.75%-70.18%-73.47%-82.03%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-0.20%+2.79%-11.87%+33.56%+114.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cel-Sci Corporation stock logo
CVM
Cel-Sci
$1.43
+10.0%
$3.29
$0.89
$13.48
$11.04M0.7700,046 shs1.11 million shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$9.40
-5.5%
$8.87
$4.82
$11.85
$921.11M1.23777,088 shs768,589 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cel-Sci Corporation stock logo
CVM
Cel-Sci
+8.33%-18.75%-70.18%-73.47%-82.03%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-0.20%+2.79%-11.87%+33.56%+114.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cel-Sci Corporation stock logo
CVM
Cel-Sci
0.00
N/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2.75
Moderate Buy$25.83174.82% Upside

Current Analyst Ratings Breakdown

Latest MGTX and CVM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Boost Price TargetOutperform$24.00 ➝ $25.00
4/22/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Boost Price TargetOverweight$26.00 ➝ $30.00
4/21/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Reiterated RatingSell (D-)
4/17/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Boost Price TargetOutperform$16.00 ➝ $24.00
3/27/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Lower Price TargetOverweight$30.00 ➝ $26.00
3/27/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Boost Price TargetBuy$14.00 ➝ $16.00
3/27/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Reiterated RatingBuy$35.00
3/9/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
UpgradeStrong SellHold
(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cel-Sci Corporation stock logo
CVM
Cel-Sci
N/AN/AN/AN/A$2.32 per shareN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$81.39M10.69N/AN/A($0.07) per share-134.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cel-Sci Corporation stock logo
CVM
Cel-Sci
-$25.41M-$9.77N/AN/AN/AN/A-226.09%-102.18%N/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$114.20M-$1.42N/AN/AN/A-140.31%-1,065.47%-53.33%N/A

Latest MGTX and CVM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2026Q2 2026
Cel-Sci Corporation stock logo
CVM
Cel-Sci
N/A-$0.67N/A-$0.67N/AN/A
5/14/2026Q1 2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.58-$0.57+$0.01-$0.57$17.00 million$0.29 million
3/26/2026Q4 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.60$0.19+$0.79$0.19$3.87 million$75.36 million
2/17/2026Q1 2026
Cel-Sci Corporation stock logo
CVM
Cel-Sci
N/A-$0.68N/A-$0.68N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cel-Sci Corporation stock logo
CVM
Cel-Sci
N/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cel-Sci Corporation stock logo
CVM
Cel-Sci
0.45
1.39
1.35
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/A
0.75
0.75

Institutional Ownership

CompanyInstitutional Ownership
Cel-Sci Corporation stock logo
CVM
Cel-Sci
12.08%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%

Insider Ownership

CompanyInsider Ownership
Cel-Sci Corporation stock logo
CVM
Cel-Sci
9.93%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cel-Sci Corporation stock logo
CVM
Cel-Sci
438.49 million7.65 millionOptionable
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
30092.57 million85.63 millionOptionable

Recent News About These Companies

MeiraGTx (MGTX) Projected to Post Earnings on Tuesday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cel-Sci stock logo

Cel-Sci NYSEAMERICAN:CVM

$1.43 +0.13 (+10.00%)
Closing price 04:10 PM Eastern
Extended Trading
$1.46 +0.03 (+1.75%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$9.40 -0.55 (-5.53%)
Closing price 04:00 PM Eastern
Extended Trading
$9.40 0.00 (0.00%)
As of 04:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.